Erectile Dysfunction

About Cetrorelix Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach.

This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Professor Andrew Schally of the U.S.

Veterans Administration in Miami.

Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan.

It was launched on the market through Merck Serono in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

In addition to the Phase 3 program in BPH, cetrorelix is also in a Phase 2 program in this same indication in Japan, sponsored by the Company's partner, Shionogi as well as in a clinical program for endometriosis sponsored by Solvay.

About AEterna Zentaris Inc.

AEterna Zentaris Inc.

is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aeternazentaris.com/.

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe ...

Read more...